Source disclosure: February 25, 2026, 15:30 JST
SUSMED,Inc. [4263.T]
TOKYO, Feb 25 (Pulse News Wire) – Susmed,inc. (4263.T) announced today that it has achieved a milestone in its joint research and development agreement with Asuka Pharmaceutical Co., Ltd.
The milestone pertains to a treatment app targeting premenstrual syndrome and premenstrual dysphoric disorder, which showed promising results in exploratory trials. Both companies agreed to advance to the next phase of development based on these findings. Under the terms of their contract, SUSMED expects to receive a milestone payment of ¥100 million.
This payment is anticipated to be recorded as part of the company’s operating revenue for the fiscal period ending June 2026. The observation period for all study participants has concluded, and SUSMED and Asuka Pharmaceutical are now analyzing the detailed results to prepare for subsequent phases of development. This milestone follows previous announcements made on September 25, 2023, and January 28, 2025, concerning the initiation of clinical studies and the signing of the joint development agreement.
AI-translated content. 🟢 Confidence: High See terms • Original filing